Recent Press Releases

New resource on health coverage, Highlights hurdles patients may face accessing needed medicines

New resource on health coverage, Highlights hurdles patients may face accessing needed medicines Washington, D.C. (October 14, 2014) — Today, the Pharmaceutical Research and Manufacturers of...

EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study

EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study TARRYTOWN, N.Y., Oct....

FDA approves labeling with abuse-deterrent features for third extended-release opioid analgesic

FDA approves labeling with abuse-deterrent features for third extended-release opioid analgesic The U.S. Food and Drug Administration today approved new labeling for Embeda (morphine sulfate and...

Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results

10/20/2014 LAVAL, Quebec, Oct. 20, 2014 /PRNewswire/ -- 2014 Third Quarter Results Total Revenue $2.1 billion; an increase of 33% over the prior year Total same store sales organic growth...

FDA Approves Abuse Deterrent Labeling for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended-Release (ER) Capsules CII

FDA Approves Abuse Deterrent Labeling for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended-Release (ER) Capsules CII EMBEDA is the first and only approved ER morphine specifically...

EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study

EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study TARRYTOWN, N.Y., Oct....

Amgen Announces 2014 Fourth Quarter Dividend

THOUSAND OAKS, Calif., Oct.

Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement

Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement THOUSAND OAKS, Calif., Oct. 17, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that it filed a lawsuit in the United States...

Lilly Announces Plan to Realign Puerto Rico Manufacturing Operations

Lilly Announces Plan to Realign Puerto Rico Manufacturing Operations INDIANAPOLIS, Oct. 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to conclude production and...

Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® and GAZYVA® in Lymphoma and Leukemia

SUNNYVALE, Calif., Oct. 16, 2014 /PRNewswire/ -- Pharmacyclics, Inc.

Abbott Acknowledged by Science Magazine as a Top Employer

Research-Driven Environment and Easy Adaptation to Change Are Key Traits that Scientists Value in their Employers

ABBOTT PARK, Ill., Oct.

Lilly Announces Plan to Realign Puerto Rico Manufacturing Operations

Manufacturing at Guayama will conclude while investments continue in Carolina

INDIANAPOLIS, Oct.

FDA Approves Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States

FDA Approves Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Approximately 100,000 People in United States Have IPF, an Irreversible and Fatal...

Roche delivers solid sales growth for the first nine months of 2014

Roche delivers solid sales growth for the first nine months of 2014 Group sales up 5% at CER1, stable in Swiss francs 4% higher sales in Pharmaceuticals Division, with strong growth of oncology...

Statement re: AbbVie's intention to reconsider recommendation

Statement re: AbbVie's intention to reconsider recommendation The Board of Shire plc (LSE: SHP, NASDAQ: SHPG) notes the announcement by AbbVie Inc. ("AbbVie") of its Board's...

Salinas Valley Memorial Healthcare System Boosts Broadband Speeds and Decreases Latency for Hundreds of Medical Practices and Facilities with Comcast Business Ethernet

New internet VPN system provides superior broadband support to help hospitals and physicians manage thousands of medical records across the county - especially those in rural and isolated location

Johnson & Johnson Reports 2014 Third-Quarter Results:

Sales of $18.5 Billion Increased 5.1% Versus 2013 Third Quarter;

NEW BRUNSWICK, N.J., Oct.

Johnson & Johnson Reports 2014 Third-Quarter Results

Sales of $18.5 Billion Increased 5.1% Versus 2013 Third Quarter; Third-Quarter EPS was $1.66 Excluding Special Items, 2014 Third-Quarter EPS of $1.50 Increased 10.3%* NEW BRUNSWICK, N.J., Oct. 14,...

Move Over Gilead? AbbVie Could Bring Serious Competition to HCV Market

Move Over Gilead? AbbVie Could Bring Serious Competition to HCV Market Gilead's Harvoni Might Be the Top Overall Performer, Says RxScorecard™, but a Discounted Triple Regimen From AbbVie...